# GC America, Inc. – FDA 483, Nov 7, 2025

Source: https://www.keypedia.com/records/483/gc-america-inc/12c238db-a04f-47df-aa31-9b7c3a2e9078

> FDA 483 for GC America, Inc. on November 07, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: GC America, Inc.
- Inspection Date: 2025-11-07
- Product Type: drugs
- Office Name: Chicago District Office
- Summary: GC America Inc., an OTC drug manufacturer in Alsip, Illinois, was inspected and received a Form 483 with four observations. The inspection revealed significant issues with data integrity and computer system controls, including unrestricted access and lack of data backup for analytical instruments, and inadequate controls for product packaging printers. Additionally, the firm failed to conduct annual product reviews, lacked a stability testing program to support product expiration dates, and did not adequately test water used in drug product manufacturing for microbiological specifications.

## Related Documents

- [WARNING_LETTER - 2012-07-13](https://www.keypedia.com/records/warning_letter/gc-america-inc/ffe8b2e0-bf56-41f0-a862-136bc5c558b9) — date: July 13, 2012

## Related Officers

- [Ramia Brzenjy](https://www.keypedia.com/people/ramia-brzenjy/b0e5e3b0-c295-4ec6-845a-95968824c16a)
- [President & Chief Operating Officer](https://www.keypedia.com/people/joseph-talanges/40d90b6c-823e-4bda-8714-7afc9033c580)

Company: https://www.keypedia.com/companies/gc-america-inc/ef0ee3f7-2cac-4212-8512-b78c9d54b20d

Office: https://www.keypedia.com/offices/chicago-district-office/a510300b-0eaf-4a33-90b5-231d95977669